On 5–6 October, India's Directorate General of Trade Remedies opened five fresh anti-dumping investigations, with China named in every one. For a handful of NSE-listed companies this matters more than Wednesday's RBI decision.

The products sound obscure — persulphates (China), clavulanic acid and its amine salt (China and the EU), certain counterbalance forklifts (China and Japan), internally grooved copper tubes and pipes (China, Thailand and Vietnam, plus a parallel countervailing-duty probe), and caprolactam (China, Russia, Thailand and the US).

Most coverage filed this under "India tightens trade defence." But three of these products are named, by name, in listed companies' filings — some as the thing destroying their margins, others as an input they cannot buy anywhere else. The filings tell you who wins and, more usefully, who quietly pays.

The copper tube probe is a gift to one company

Internally grooved copper tubes (IGTs) are the thin, grooved tubes inside every air conditioner's heat exchanger. Hindalco is building India's first plant for them.

Per Hindalco's FY2024 annual report, it is installing a copper tube facility at GIDC Waghodia, Vadodara for roughly ₹586 crore under the government's PLI scheme for white goods — "the first plant in India to produce copper tubes (mainly inner grooved)" for the air-conditioning and refrigeration industry. Its Investor Day 2025 material explains why: "Almost entire of India's Inner Grooved Tubes (IGT) demand is currently met through imports."

Then the number that matters. Hindalco's FY2025 annual report puts planned capacity at 25 KTPA in Phase 1 by FY2026-27, scaling to 50 KTPA in Phase 2 — against a segment where "the total market size is estimated to be around 20-25 KTPA." Phase 1 alone is roughly the entire Indian market, and per its Q1 FY27 presentation (7 August 2026) the plant is "fully operational and scaling up." A duty would land precisely as the only domestic producer finishes ramping.

The AC makers already told you where they buy them

The other side is on record. On Blue Star's May 2023 earnings call: "India cannot avoid importing components — inner grooved copper wire, copper tubes — it has to be imported. India, there is one manufacturer trying to do that under PLI."

By its Q4 FY25 call (14 May 2025), Blue Star named the exact channel the probe targets: "Copper tubes, inner grooved copper tubes were getting imported from FTA countries like Vietnam predominantly." Crucially, it added that "with Hindalco we were the first one to sign the MOU for sourcing." Blue Star hedged early.

Others disclosed dependence instead. Epack Durable described the same route in July 2025 as unresolved: "the customs issue is linked to imports of copper tube, which the industry does from the ASEAN country," with show-cause notices reportedly issued to over 2,000 importers, and "the industry continues to give bank guarantees."

A duty closes exactly that ASEAN route. Blue Star has contracted supply; the contract manufacturers have bank guarantees.

Caprolactam: the squeeze nobody is pricing

This is the sharpest case, because both sides are listed.

GSFC is the injured domestic producer and has said so for two years. On its Q1 FY25 call, management blamed subdued domestic prices on "dumping of cheap Chinese caprolactam, melamine and basic nylon 6," with the capro-benzene spread falling year-on-year from $730/MT to $582/MT. Its Q3 FY25 call pegged caprolactam breakeven at "just about $1,600" a tonne; by May 2025 GSFC noted international prices "falling below US $1,200 per metric ton," and its November 2025 call still flagged "continued influx of low-priced Chinese imports." In May 2024 it sized the mismatch: GSFC runs about 90,000 tonnes of active caprolactam production, while China was "going to recently commission 4 lakh ton caprolactam plants."

Now read Century Enka's FY2026 annual report risk table, which names caprolactam as its critical raw material exposed to "supply chain constraints, single supply source in India, geopolitical factors, and limited sources outside China." Its stated mitigations: maximise domestic sourcing under long-term contracts, and develop alternate global suppliers. A probe covering China, Russia, Thailand and the US narrows precisely those alternates, leaving one domestic supplier. On its July 2026 call: "we also take from the domestic supplier and we also import."

The asymmetry is the point: Century Enka's input may get a duty, but its output will not. Per its August 2025 call, roughly 20% of nylon tyre cord fabric demand is met by imports entering "under advanced license" for tyre exports, "so to that extent, the domestic capacity remains underutilized."

Forklifts and antibiotics

Action Construction Equipment makes forklift trucks — its November 2025 presentation shows material handling capacity of 2,700 units within 26,700 total — and it has already written the script for reading this news. On its 13 November 2025 call, about a different product: "The recent recommendation to impose anti-dumping duties on certain cranes import i.e. crawler cranes and truck cranes from China is a significant structural positive for the domestic construction equipment sector including our Company."

The clavulanic acid probe hits the formulators who buy it. Alkem's FY2025 annual report shows CLAVAM (amoxicillin + clavulanic acid) as its third-largest brand at ₹578.0 crore, with 16.3% molecule market share (IQVIA March 2025 data). On persulphates, no listed pure-play producer appears in the NSE filings corpus — that leg looks untradeable.

What retail investors should do

Separate initiation from outcome. An anti-dumping probe is a start, not a duty: DGTR takes months to reach provisional findings and can recommend nothing at all. Do not buy a duty that hasn't been levied.

What you can do today is check which side of each probe a company sits on, and whether it has already hedged. Blue Star disclosed a domestic sourcing MOU; Epack Durable disclosed unresolved import exposure. GSFC disclosed caprolactam losing money below $1,600/MT; Century Enka disclosed a single Indian source for the same molecule. Those are the sentences that move when a duty is announced — and they are already public. Watch for DGTR provisional findings over the next two to three quarters, and whether Century Enka starts quantifying input-cost impact on calls.

Size it honestly, though. Each of these is a single-product exposure inside a much larger company. For Hindalco, IGTs are a rounding error against a copper business that posted ₹17,232 crore of revenue and ₹918 crore of EBITDA in Q1 FY27. The read-through is real, but this is a margin story, not a re-rating story.

Data sourced from company filings on NSE via Xaro.